Evaluation of miR-103 Expression in Peripheral Blood Mononuclear Cells of Type 2 Diabetic and Prediabetic Rats

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Genetics and Molecular Biology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Medical Biotechnology, School of Medicine, Arak University of Medical Sciences, Arak, Iran

3 Department of Biology, School of Sciences, University of Isfahan, Isfahan, Iran

4 Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Type 2 diabetes (T2D) is the most prevalent chronic metabolic disease. MicroRNAs act as regulators of gene expression by inhibiting translation or promoting degradation of target mRNAs. Recent reports indicate that microRNAs can play important role in establishment of diabetes and has roles in type 2 diabetes different aspects including insulin insensitivity. To detect a noninvasive screening method for type 2 diabetes, we evaluated the expression level of miR-103 in peripheral blood mononuclear cells (PBMC) samples from pre-diabetes and type 2 diabetes rats in compare to normal group (n = 8 in each group) using real-time polymerase chain reaction (RT-PCR) method.Methods: Animal model type 2 diabetes was made with combination of high-fat diet (HFD) and low dose of stretozotocin (STZ) injection. Blood glucose level, serum insulin, and cholesterol, low density lipid and triglyceride levels were measured after 10-weeks diet interference. Peripheral blood mononuclear cells isolated from blood samples of three groups of animals, and then total RNA was obtained using Trizol reagent. All microRNAs converted to cDNA (complementary DNA). Expression level of rno-miR-103 was assessed via one-step SYBR GreenⅠ relative real-time polymerase chain reaction, using specific LNA TM qRT-PCR primer set for amplifying rno-miR-103. Statistical analysis was performed using SPSS20 software.Findings: Combination of high-fat diet and low dose of stretozotocin effectively induced type 2 diabetes in rats. rno-miR-103 expression level in peripheral blood mononuclear cells samples of pre-diabetic (high-fat diet) subjects and type 2 diabetes rats significantly elevated in compare to normal group.Conclusion: The high-fat diet/stretozotocin-induced type 2 diabetes animal model is the most suitable way for mimicking pre-diabetes and diabetes in men. The result of miRNA expression assay in peripheral blood mononuclear cells indicates the importance of rno-miR-103 in type 2 diabetes pathogenesis in early stages and has potential as a clinically useful noninvasive source to predict the disease status.

Keywords

References

  1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3): 311-21.
  2. Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep 2009; 9(3): 193-9.
  3. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9(3): 193-205.
  4. Schlienger JL. Type 2 diabetes complications. Presse Med 2013; 42(5): 839-48.
  5. Sanghera DK, Blackett PR. Type 2 Diabetes Genetics: Beyond GWAS. J Diabetes Metab 2012; 3(198).
  6. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19(4): 491-503.
  7. Pandey AK, Agarwal P, Kaur K, Datta M. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 2009; 23(4-6): 221-32.
  8. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012; 93(4): 583-93.
  9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
  10. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, et al. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005; 434(7031): 338-45.
  11. Behm-Ansmant I, Rehwinkel J, Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol 2006; 71: 523-30.
  12. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006; 25(46): 6163-9.
  13. Ambros V. The functions of animal microRNAs. Nature 2004; 431(7006): 350-5.
  14. Aravin A, Tuschl T. Identification and characterization of small RNAs involved in RNA silencing. FEBS Lett 2005; 579(26): 5830-40.
  15. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
  16. van Iterson M, Bervoets S, de Meijer EJ, Buermans HP, 't Hoen PA, Menezes RX, et al. Integrated analysis of microRNA and mRNA expression: adding biological significance to microRNA target predictions. Nucleic Acids Res 2013; 41(15): e146.
  17. Ha TY. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw 2011; 11(3): 135-54.
  18. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432(7014): 226-30.
  19. Tang X, Muniappan L, Tang G, Ozcan S. Identification of glucose-regulated miRNAs from pancreatic {beta} cells reveals a role for miR-30d in insulin transcription. RNA 2009; 15(2): 287-93.
  20. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21(11): 2785-94.
  21. Ling HY, Ou HS, Feng SD, Zhang XY, Tuo QH, Chen LX, et al. Changes IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 2009; 36(9): e32-e39.
  22. Rottiers V, Najafi-Shoushtari SH, Kristo F, Gurumurthy S, Zhong L, Li Y, et al. MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol 2011; 76: 225-33.
  23. Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 2010; 394(3): 792-7.
  24. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, et al. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009; 9: 353.
  25. Zeng XL, Zhang SY, Zheng JF, Yuan H, Wang Y. Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer. Chin Med J (Engl) 2013; 126(23): 4510-6.
  26. Mohr S, Liew CC. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 2007; 13(10): 422-32.
  27. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004; 2(11): e363.
  28. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
  29. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011; 44(5): 839-47.
  30. Wilfred BR, Wang WX, Nelson PT. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 2007; 91(3): 209-17.
  31. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000; 49(11): 1390-4.
  32. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52(4): 313-20.
  33. Roberts TC, Coenen-Stass AM, Wood MJ. Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum. PLoS One 2014; 9(2): e89237.
  34. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50(4): 298-301.
  35. Herrera BM, Lockstone HE, Taylor JM, Wills QF, Kaisaki PJ, Barrett A, et al. MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of Type 2 Diabetes. BMC Med Genomics 2009; 2: 54.
  36. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18(10): 997-1006.
  37. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3(11): e3694.
  38. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010; 285(23): 17442-52.
  39. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107(6): 810-7.
  40. Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One 2011; 6(8): e22839.
  41. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 2011; 48(1): 61-9.
  42. Collares CV, Evangelista AF, Xavier DJ, Rassi DM, Arns T, Foss-Freitas MC, et al. Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res Notes 2013; 6: 491.
  43. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011; 474(7353): 649-53.
  44. Li S, Chen X, Zhang H, Liang X, Xiang Y, Yu C, et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009; 50(9): 1756-65.
Journal of Isfahan Medical School
Volume 32, Issue 306 - Serial Number 306
September and October 2014
Pages 1746-1756

Files

History

  • Receive Date: 28 April 2014
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics